造血干细胞移植治疗慢性粒细胞白血病中监测BCR/ABL融合基因的应用

The Application of Monitoring BCR/ABL Fusion Gene in the Therapy of Chronic Myeloid Leukemia by Allogeneic Hematopoietic Stem Cell Transplantation

目的 研究应用筑巢式逆转录多聚合酶链反应法 (nested RT PCR)监测bcr/abl融合基因mRNA在异基因造血干细胞移植治疗慢性粒细胞白血病 (CML)效果监测方面的价值。方法 应用RT PCR方法定期检测异基因造血干细胞移植治疗慢性粒细胞白血病患者前后bcr/abl融合基因表达情况。结果 异基因造血干细胞移植治疗组完全血液学缓解率为 10 0 % ,分子生物学缓解率分别为87.5 %。结论 bcr/abl融合基因监测可以作为CML评价疗效的指标 ,适用于微小残留病变的监测。

Objective To investigate the value of nested reverce transoripiton polymerase chain reaction (nested-RT-PCR) in detecting BCR/ABL fusion gene in monitoring the response to therapy in chronic myeloid leukemia patients by allogeneic hematopoietic stem cell transplantation(allo-HSCT). Methods Monitoring the expression of BCR/ABL fusion gene by using nested-RT- PCR in chronic myeloid leukemia patients before and after treating patients applying allogenetic hematopoietic stem cell transplantation (allo-HSCT).Result The percentage of patients who had achieved complete hematological response induced by allo-HSCT was 100%; The rate of complete cytogenetic response induced by allo-HSCT was 87.5%.Conclusions Monitoring the BCR/ABL fusion gene can be used to evaluate the efficacy of this therapy and to detect the minimal residual disease (MRD).